-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
-
XOMA Corporation Announces Closing of Tender Offer
April 3, 2024
-
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
-
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 8, 2024
-
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
-
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
-
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
-
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
-
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 8, 2024
-
XOMA Announces Stock Repurchase Program of up to $50 Million
January 2, 2024
-
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
-
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
-
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 7, 2023
-
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023